Resource | Unit price | Annual resource use | Total cost |
---|
ACARIZAX | Pharmacotherapy | ACARIZAX | Pharmacotherapy |
---|
ACARIZAX tableta
| €2.53 | 365 | 0 | €923 | €0 |
GP visitsb
| €29.35 | 0.175 | 0.105 | €5.13 | €3.07 |
Emergency room visitsb
| €74.96 | 0.010 | 0.025 | €0.75 | €1.89 |
ICS daily dose (μg)c
| €18.14 | 563 | 555 | €373 | €363 |
SABA intake (doses)c
| €22.15 | 266 | 297 | €9.82 | €10.96 |
- Three drugs and two other medical resources were included as parameters in the analysis. Resource use was based on data recorded in MT-04 and, therefore, they relate specifically to allergic asthma patients. The values have been multiplied by the unit price of each resource to generate total costs. These costs were applied to a one year period, and applied equally across all years in the analysis (with costs also discounted at 3 % per year in line with German guidelines)
-
aSource: http://www2.lauer-fischer.de/
-
bSource: http://www.kbv.de/html/
-
cSource: https://www.gkv-spitzenverband.de